Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMZ0F65)

Drug Name

Contezolid Drug Info

Synonyms

MRX-I; UNII-B669M62ELP; B669M62ELP; CHEMBL3287379; 1112968-42-9; 4(1H)-Pyridinone, 2,3-dihydro-1-(2,3,6-trifluoro-4-((5S)-5-((3-isoxazolylamino)methyl)-2-oxo-3-oxazolidinyl)phenyl)-; 4(1H)-Pyridinone, 2,3-dihydro-1-[2,3,6-trifluoro-4-[(5S)-5-[(3-isoxazolylamino)methyl]-2-oxo-3-oxazolidinyl]phenyl]-; Contezolid [USAN]; SCHEMBL5945221; BDBM50017203; DB12796

Indication

Disease Entry	ICD 11	Status	REF
MRSA infection	1D01.0Y	Phase 2	[1]
Skin infection	1F28-1G0Z	Phase 2	[2]

Cross-matching ID

PubChem CID: 25184541
CAS Number: CAS 1112968-42-9
TTD Drug ID: DMZ0F65

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Protein synthesis (hPRO synth)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Contezolid acefosamil	DMMOHUA	Acute bacterial skin infection	1C41	Phase 2	[2]
ARV-1801	DMUMFDU	Melioidosis	1C42	Phase 2	[3]
Zilascorb (2H)	DM3IRES	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 2	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Protein synthesis (hPRO synth)	TTLIZBJ	NOUNIPROTAC	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	MICURX PHARMACEUTICALS COMPLETES PHASE 1 TRIAL FOR MRX-I, A NEXT-GENERATION ANTIBIOTIC. Micurx pharmaceuticals.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
4	Zilascorb(2H), a new reversible protein synthesis inhibitor: clinical study of an oral preparation. Anticancer Drugs. 1997 Mar;8(3):296-303.